ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Analyst Earnings Estimates
NASDAQ:RARE - Nasdaq - US90400D1081 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 363.3M 3.39% | 434.249M 19.53% | 560.23M 29.01% | 665.02M 18.70% | 842.97M 26.76% | 1.243B 47.45% | 1.663B 33.79% | 2.332B 40.23% | 2.923B 25.34% | 3.357B 14.85% | 4.199B 25.08% | |
| EBITDA YoY % growth | -630.68M -71.17% | -543.202M 13.87% | -500.43M 7.87% | -428.475M 14.38% | -297.169M 30.64% | 74.677M 125.13% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -648.9M -70.00% | -569.208M 12.28% | -535.973M 5.84% | -478.608M 10.70% | -352.233M 26.40% | -80.166M 77.24% | 274.45M 442.35% | 797.58M 190.61% | 1.146B 43.68% | 1.35B 17.80% | 2.118B 56.89% | |
| Operating Margin | -178.61% | -131.08% | -95.67% | -71.97% | -41.78% | -6.45% | 16.50% | 34.20% | 39.21% | 40.21% | 50.44% | |
| EPS YoY % growth | -10.11 -50.67% | -8.33 17.61% | -6.34 23.89% | -5.00 21.20% | -3.48 30.36% | -0.72 79.41% | 2.15 399.54% | 6.81 217.30% | 11.28 65.67% | 12.27 8.75% | 15.37 25.27% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.26 9.66% | -1.16 16.81% | -1.13 27.81% | -1.17 -0.08% | -1.08 15.00% | -0.64 44.61% |
| Revenue Q2Q % growth | 170.23M 22.03% | 189.07M 14.67% | 176.97M 27.05% | 197.31M 18.51% | 213.67M 25.52% | 270.26M 42.94% |
| EBITDA Q2Q % growth | -118.698M -12.49% | -118.863M -37.04% | -24.54M 81.68% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -118.855M 9.95% | -112.288M 8.17% | -118.89M 16.82% | -111.444M -3.30% | -102.954M 13.38% | -59.555M 46.96% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.17 23.03% | -1.32 | 0.15 | 11.68% |
| Q1 2025 Q2Q % growth | -1.57 22.66% | -1.65 | 0.08 | 4.60% |
| Q4 2024 Q2Q % growth | -1.39 8.55% | -1.32 | -0.07 | -5.63% |
| Q3 2024 Q2Q % growth | -1.40 37.22% | -1.48 | 0.08 | 5.37% |
| Q2 2024 Q2Q % growth | -1.52 32.44% | -1.73 | 0.21 | 12.01% |
| Q1 2024 Q2Q % growth | -2.03 12.88% | -1.77 | -0.26 | -14.94% |
| Q4 2023 Q2Q % growth | -1.52 29.63% | -1.65 | 0.13 | 7.99% |
| Q3 2023 Q2Q % growth | -2.23 36.29% | -2.12 | -0.11 | -5.20% |
| Q2 2023 Q2Q % growth | -2.25 0.44% | -2.12 | -0.13 | -6.35% |
| Q1 2023 Q2Q % growth | -2.33 -6.39% | -2.02 | -0.31 | -15.58% |
| Q4 2022 Q2Q % growth | -2.16 -20.67% | -2.18 | 0.02 | 1.14% |
| Q3 2022 Q2Q % growth | -3.50 -224.07% | -1.85 | -1.65 | -89.21% |
| Q2 2022 Q2Q % growth | -2.26 -24.86% | -1.79 | -0.47 | -26.47% |
| Q1 2022 Q2Q % growth | -2.19 -7.88% | -1.80 | -0.39 | -21.97% |
| Q4 2021 Q2Q % growth | -1.79 -383.78% | -1.37 | -0.42 | -30.74% |
| Q3 2021 Q2Q % growth | -1.08 4.42% | -1.44 | 0.36 | 24.80% |
| Q2 2021 Q2Q % growth | -1.81 -541.46% | -1.36 | -0.45 | -33.07% |
| Q1 2021 Q2Q % growth | -2.03 -6.28% | -1.26 | -0.77 | -60.89% |
| Q4 2020 Q2Q % growth | -0.37 77.16% | -1.18 | 0.81 | 68.76% |
| Q3 2020 Q2Q % growth | -1.13 42.35% | -1.28 | 0.15 | 11.98% |
| Q2 2020 Q2Q % growth | 0.41 121.69% | -1.57 | 1.98 | 126.03% |
| Q1 2020 Q2Q % growth | -1.91 -4.95% | -1.72 | -0.19 | -11.34% |
| Q4 2019 Q2Q % growth | -1.62 | -1.68 | 0.06 | 3.70% |
| Q3 2019 Q2Q % growth | -1.96 | -1.71 | -0.25 | -14.62% |
| Q2 2019 Q2Q % growth | -1.89 | -1.73 | -0.16 | -9.20% |
| Q1 2019 Q2Q % growth | -1.82 | -1.77 | -0.05 | -2.72% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 166.496M 13.24% | 164.82M | 1.676M | 1.02% |
| Q1 2025 Q2Q % growth | 139.292M 27.99% | 146.7M | -7.408M | -5.05% |
| Q4 2024 Q2Q % growth | 164.877M 29.42% | 158.5M | 6.377M | 4.02% |
| Q3 2024 Q2Q % growth | 139.494M 42.27% | 138.51M | 984K | 0.71% |
| Q2 2024 Q2Q % growth | 147.026M 35.75% | 125.64M | 21.386M | 17.02% |
| Q1 2024 Q2Q % growth | 108.833M 8.30% | 118.33M | -9.497M | -8.03% |
| Q4 2023 Q2Q % growth | 127.392M 23.32% | 121.77M | 5.622M | 4.62% |
| Q3 2023 Q2Q % growth | 98.052M 8.11% | 111.82M | -13.768M | -12.31% |
| Q2 2023 Q2Q % growth | 108.309M 21.29% | 106.9M | 1.409M | 1.32% |
| Q1 2023 Q2Q % growth | 100.496M 25.78% | 106.78M | -6.284M | -5.88% |
| Q4 2022 Q2Q % growth | 103.3M 23.86% | 107.22M | -3.92M | -3.66% |
| Q3 2022 Q2Q % growth | 90.7M 11.15% | 98.121M | -7.421M | -7.56% |
| Q2 2022 Q2Q % growth | 89.3M 2.64% | 89.265M | 35K | 0.04% |
| Q1 2022 Q2Q % growth | 79.9M -19.62% | 85.327M | -5.427M | -6.36% |
| Q4 2021 Q2Q % growth | 83.4M -8.85% | 85.471M | -2.071M | -2.42% |
| Q3 2021 Q2Q % growth | 81.6M 0.12% | 83.178M | -1.578M | -1.90% |
| Q2 2021 Q2Q % growth | 87M 41.00% | 87.6M | -600K | -0.68% |
| Q1 2021 Q2Q % growth | 99.4M 173.83% | 78.58M | 20.82M | 26.50% |
| Q4 2020 Q2Q % growth | 91.5M 157.02% | 71.955M | 19.545M | 27.16% |
| Q3 2020 Q2Q % growth | 81.5M 215.89% | 56.107M | 25.393M | 45.26% |
| Q2 2020 Q2Q % growth | 61.7M 156.02% | 39.901M | 21.799M | 54.63% |
| Q1 2020 Q2Q % growth | 36.3M 99.45% | 37.477M | -1.177M | -3.14% |
| Q4 2019 Q2Q % growth | 35.6M | 32.798M | 2.802M | 8.54% |
| Q3 2019 Q2Q % growth | 25.8M | 29.699M | -3.899M | -13.13% |
| Q2 2019 Q2Q % growth | 24.1M | 22.975M | 1.125M | 4.90% |
| Q1 2019 Q2Q % growth | 18.2M | 18.663M | -463K | -2.48% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.5% | 4.25% | 0% | 6.69% |
| Revenue | 1.85% | 0.58% | -0.2% | 0.02% |